It is true, for longterm shareholders, the stock has performed poorly, however, the basic science is sound and if the company actually files the NDA this year, the future is promising. No illusions, the regulatory path ahead is no walk in the park, but it looks doable. With FDA approval and the extremely low "float", the risk/reward is quite attractive.
News 
Market Data 
Discover 
